TRASTUZUMAB INJECTION 440MG
| Generic Name | Trastuzumab |
|---|---|
| Strength | 440 mg |
| Dosage Form | Injection (lyophilized powder) |
| Route of Administration | Intravenous (IV) |
| Therapeutic Class | Anticancer/Monoclonal Antibody |
| Indications | HER2-positive breast cancer, HER2-positive gastric cancer |
| Prescription Required | Yes |
| Storage | Store refrigerated at 2°C–8°C; do not freeze |
| Manufacturer | As per pack details |
TRASTUZUMAB INJECTION 440MG
Trastuzumab Injection 440mg is a targeted biologic therapy designed for the treatment of HER2-positive cancers, offering a precise approach to modern cancer care. As a monoclonal antibody, it specifically targets the HER2 receptor that promotes aggressive tumor growth in certain cancer cells. This precision therapy is widely used in patients diagnosed with HER2-overexpressing breast cancer and advanced gastric or gastro-oesophageal junction adenocarcinoma, helping improve treatment outcomes when used as part of a specialist-guided regimen.
The mechanism of action of trastuzumab focuses on blocking HER2 signaling pathways that drive cancer cell proliferation. By binding to HER2 receptors, it slows tumor growth and activates the body’s immune system to recognize and destroy malignant cells. Administered intravenously in a controlled clinical setting, this therapy ensures accurate dosing and careful monitoring, making it a cornerstone option in targeted cancer treatment protocols for eligible patients.
Trastuzumab Injection 440 mg is an advanced biologic product that plays a critical role in modern oncology treatment strategies. Its targeted design allows oncologists to personalize therapy for HER2-positive cancer patients while minimizing damage to healthy tissues. As an essential oncology medication, this product supports long-term disease management and is prescribed under expert supervision to ensure safety, effectiveness, and optimal therapeutic response.
Product Features
- Monoclonal antibody targeted therapy
- Specifically indicated for HER2-positive cancers
- Inhibits HER2-mediated tumour cell proliferation
- Enhances immune-mediated cancer cell destruction
- Administered via intravenous infusion
- Prescription-only oncology biologic
How It Helps
- Targets HER2 receptors to slow the growth of cancer cells
- Helps reduce tumour progression in HER2-positive cancers
- Supports the immune system in destroying malignant cells
- Improves treatment outcomes when used in targeted therapy plans
Reviews
There are no reviews yet.